The Figure shows the risk reduction with dabigatran 150 mg vs warfarin for all of the components of the primary endpoint.[104]
The reduction was statistically significant for all of the components (all strokes, ischemic strokes, hemorrhagic strokes) except systemic embolism (HR 0.61, NS).  All endpoints were reduced with dabigatran versus warfarin, and they were done so similarly in all prespecified subgroups.

 Reiffel JA. Am J Med 2013; 126: 00-00.